Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries BioSpaceThe FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug's overall risk-benefit profile.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. RegulatoryImmunology & InflammationRead full story Post navigation Previous: IO Shuts Down Following Regulatory RoadblocksNext: Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
